Raymond James & Associates Denali Therapeutics Inc. Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$20.63 - $30.17 $2,826 - $4,133	-137 Reduced 1.37%	9,894 $204,000
Q2 2023 Jul 25, 2023	SELL	$23.37 - $32.96 $32,157 - $45,352	-1,376 Reduced 12.06%	10,031 $296,000
Q1 2023 Apr 14, 2023	BUY	$21.91 - $32.67 $32,645 - $48,678	1,490 Added 15.02%	11,407 $262,000
Q4 2022 Feb 08, 2023	BUY	$26.28 - $33.92 $260,618 - $336,384	9,917 New	9,917 $275,000
Q1 2022 May 11, 2022	SELL	$29.0 - $47.27 $142,854 - $232,852	-4,926 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$42.59 - $55.02 $53,024 - $68,499	-1,245 Reduced 20.18%	4,926 $220,000
Q3 2021 Nov 02, 2021	SELL	$48.48 - $78.23 $10,568 - $17,054	-218 Reduced 3.41%	6,171 $311,000
Q2 2021 Aug 11, 2021	SELL	$50.3 - $78.44 $55,128 - $85,970	-1,096 Reduced 14.64%	6,389 $501,000
Q1 2021 May 14, 2021	SELL	$53.8 - $81.53 $2,528 - $3,831	-47 Reduced 0.62%	7,485 $427,000
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $277,855 - $704,693	7,532 New	7,532 $631,000

226

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.